Concepedia

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti, Elena Castro, Tanya B. Dorff, Adam Stirling, Arnulf Stenzl, Mark T. Fleming, Celestia S. Higano, Fred Saad,

The Lancet Oncology · 2021 · 277 citations · 26 references

DOIFull text

Open access

Concepts

References

26

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

C. J. Clopper, E. S. Pearson · Biometrika · 1934 · 4.8K citations

, , +16

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.2K citations · Full text

, , +17

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Junko Murai, Shar-yin N. Huang, Benu Brata Das et al. · Cancer Research · 2012 · 2.2K citations · Full text

, , +17

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

, , +14

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher, Michael J. Morris, Walter M. Stadler et al. · Journal of Clinical Oncology · 2016 · 1.6K citations

, , +17